<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166804">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926224</url>
  </required_header>
  <id_info>
    <org_study_id>M111</org_study_id>
    <nct_id>NCT00926224</nct_id>
  </id_info>
  <brief_title>Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients</brief_title>
  <official_title>Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Echosens</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Echosens</source>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate the diagnostic performance of the XL probe
      for estimating degree of liver fibrosis/cirrhosis in obese patients &gt; 28 kg/m² with various
      liver diseases in patients with chronic liver disease scheduled for a liver biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnosis accuracy for the assement of significant fibrosis and cirrhosis</measure>
    <time_frame>at enrollement</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Liver Fibrosis</condition>
  <condition>Cirrhosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan M and XL probes</intervention_name>
    <description>Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient of at least 18 years of age

          -  Patient able to give written informed consent form

          -  Patient with a BMI superior or equal to 28kg/m²

          -  Patient scheduled to have a liver biopsy within 1 month after the enrollment or with
             a liver biopsy performed within 6 months before the enrollment.

          -  Patient for which abdominal ultrasound is technically possible

        Exclusion Criteria:

          -  Unable or unwilling to provide written informed consent

          -  Confirmed diagnosis and/or history of malignancy, or other terminal disease

          -  Patients with clinical ascites

          -  Pregnant women

          -  Patient with a BMI &lt; 28 kg/m²

          -  Patients with any active implantable medical device (such as pacemaker or
             defibrillator)

          -  Transplanted patient and patient with heart disease

          -  Refusal to undergo a liver biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Calgary University Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Luc University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>November 15, 2010</lastchanged_date>
  <firstreceived_date>June 22, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Celine Fournier</name_title>
    <organization>Echosens</organization>
  </responsible_party>
  <keyword>Adult patients with chronic liver disease scheduled for a liver biopsy and a BMI superior or equal to 28 kg/m²</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
